化合物NS 1209 T4009

Product Introduction
Bioactivity


英文名: NS 1209

描述: NS 1209 (SPD 502) 是一种 AMPA 受体拮抗剂。

体内活性: NS1209 could be safely administered to rats undergoing electrically induced SE at doses up to 50 mg/kg followed by intravenous infusion of 5 mg/kg for up to 24h. NS1209 administered as a bolus dose of 10-50 mg/kg (i.p. or i.v.) followed by infusion of 4 or 5 mg/kg h (i.v.) for 2-24h effectively discontinued electrically induced SE in all animals within 30-60 min, and there was no recurrence of SE after a 24-h infusion. Kainate-induced SE was similarly blocked by 10 or 30 mg/kg NS1209 (i.v.). To compare the efficacy and neuroprotective effects of NS1209 with those of diazepam (DZP), one group of rats received DZP (20 mg/kg, i.p. and another dose of 10 mg/kg 6h later). By using the administration protocols described, the anticonvulsant effect of NS1209 was faster and more complete than that of DZP. NS1209 treatment (20 mg/kg bolus followed by 5 mg/kg h infusion for 24 h) was neuroprotective against SE-induced hippocampal neurodegeneration, but to a lesser extent than DZP.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : Limited Solubility


关键字: NS1209 | NS 1209 | SPD-502 | SPD502 | NS-1209

相关产品: AZD 9272 | TC-N 22A | Memantine hydrochloride | CDPPB | CBiPES hydrochloride | Fenobam | Cyclothiazide | cis-PDA | HexylHIBO | BMT-145027

化合物NS 1209 T4009信息由TargetMol中国为您提供，如您想了解更多关于化合物NS 1209 T4009报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途